GenSight Biologics Announces Publication Analyzing Visual Parameters of ND4-LHON Subjects before LUMEVOQ® treatment in Phase III Trials

Ophthalmology Futures Forums – Euro Retina Virtual Forum, September 8, 2021

UK MHRA grants GenSight Biologics’ LUMEVOQ® ophthalmic gene therapy Promising Innovative Medicine designation

2021 ISGEDR Meeting (International Society for Genetic Eye Diseases & Retinoblastoma)

Clinical Data on GenSight Biologics’ LUMEVOQ® and GS030 Gene Therapies to be Presented at 2021 ISGEDR and Several Investor and Industry Meetings in September

GenSight Biologics Announces Publication of RESTORE Study Data Demonstrating Sustained Efficacy 3 Years After Unilateral Injection of LUMEVOQ®

OIS European Innovation Showcase – Virtual

French Retail Investors Webcast on the Topline Results from REFLECT Phase III Clinical Trial of LUMEVOQ®

KOL Webcast on the Topline Results from REFLECT Phase III Clinical Trial of LUMEVOQ®

GenSight Biologics to Host Key Opinion Leader Webcasts on the Topline Results from REFLECT Phase III Clinical Trial of LUMEVOQ®